Back to Journals Journal of Inflammation Research Volume 17 Revolutionizing Treatment Strategies for Autoimmune and Inflammatory Disorders: The Impact of Dipeptidyl-Peptidase 4 Inhibitors Authors Rahim K, Shan M, Ul Haq I, Nawaz MN , Maryam S , Alturki MS, Al Khzem AH , Metwally K, Cavalu S, Alqifari SF , Yahya G Received 18 October 2023 Accepted for publication 9 March 2024 Published 23 March 2024 Volume 2024:17 Pages 18971917 DOI Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 2 Editor who approved publication: Dr Adam Bachstetter Kashif Rahim, 1 Muhammad Shan, 2 Ihtisham Ul Haq, 3 5 Muhammad Naveed Nawaz, 2 Sajida Maryam, 3, 4 Mansour S Alturki, 6 Abdulaziz H Al Khzem, 6 Kamel Metwally, 7 Simona Cavalu, 8 Saleh F Alqifari, 9 Galal Yahya 10 1 School of Life Science and Technology, Beijing University of Chemical Technology, Beijing, 100029, Peoples Republic of China

GLP-1 receptor agonist drugs are not just shaking up the world of obesity and diabetes medicine: a growing body of research suggests these drugs could help prevent and possibly treat Alzheimers disease, too
Can Jardiance cause hypoglycemia
Typically, most people start to notice gradual weight loss between weeks 5 and 9, but this can vary depending on the individual
The dual mechanism of action of Tirzepatide provides an edge in achieving glycemic targets, with studies indicating superior glycemic control and noteworthy weight reduction benefits for patients
This is what sets Nooms approach to weight loss medication apart. The Noom Taper-Off Guarantee Today Noom is also announcing its Taper-Off Guarantee to those who wish to taper off the medication